Cargando…
Opana ER (Oxymorphone)–Induced Thrombotic Microangiopathy: An Atypical Presentation in a Patient With Hepatitis C
Oxymorphone is a semisynthetic extended release opiate used to treat moderate to severe chronic pain. The Food and Drug Administration approved the oral form of oxymorphone available as Opana and Opana ER (extended release) since 2006. The Food and Drug Administration and the Centers for Disease Con...
Autores principales: | Mehmood, Hassan, Khan, Muzammil, Marwat, Asghar, Joshi, Medha, Malhotra, Varun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802609/ https://www.ncbi.nlm.nih.gov/pubmed/29435466 http://dx.doi.org/10.1177/2324709618756423 |
Ejemplares similares
-
Thrombotic Microangiopathy Secondary to Intravenous Abuse of Opana® ER
por: Thakur, Kamia, et al.
Publicado: (2017) -
Opana-induced thrombotic microangiopathy masquerading as thrombotic thrombocytopenic purpura
por: Ban, Byung H., et al.
Publicado: (2017) -
Bilateral exudative retinal detachments due to thrombotic microangiopathy associated with intravenous abuse of Opana ER
por: Aseem, Fazila, et al.
Publicado: (2018) -
Opana(®) ER induced thrombotic thrombocytopenic purpura
por: Kotbi, Nabil, et al.
Publicado: (2015) -
Clostridium difficile Colitis Leading to Reactive Arthritis: A Rare Complication Associated With a Common Disease
por: Marwat, Asghar, et al.
Publicado: (2018)